Core Viewpoint - AVITA Medical, Inc. is actively engaging with investors through participation in three upcoming investor conferences in September 2025, highlighting its commitment to investor relations and market presence [1][2]. Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions aimed at optimizing wound healing and accelerating patient recovery [4]. - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ Cells for improved clinical outcomes [4]. - In addition to RECELL, AVITA holds exclusive rights in the U.S. for manufacturing and distributing PermeaDerm and Cohealyx™, both of which are innovative wound care products [4]. International Market Presence - The RECELL System is approved for a variety of applications in international markets, including Australia, Europe, and Japan, demonstrating its global reach and regulatory compliance [5]. Upcoming Events - AVITA Medical will host investor meetings at the Cantor Global Healthcare Conference on September 4, 2025, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11, 2025 [8]. - A live audio webcast of the Morgan Stanley fireside chat featuring CEO Jim Corbett will be available for replay for 90 days on the company's Investor Relations website [3].

Core Insights - AVITA Medical, Inc. has appointed Dr. Michael Tarnoff as a non-executive Director to its Board of Directors, effective August 6, 2025, to enhance its focus on patient-centric wound-healing technologies [1][2] - The company has also announced the resignation of Lou Panaccio as Board Chair, with Cary Vance elected to take over the position effective August 7, 2025 [2][3] Company Developments - Dr. Tarnoff's extensive experience includes 23 years at Tufts Medical Center and leadership roles at Medtronic and Covidien, which will contribute to AVITA's growth in therapeutic acute wound care [4][7] - Cary Vance, with over 25 years of executive leadership in the healthcare industry, is expected to drive innovation and support the company's mission [5][7] Product and Technology Focus - AVITA Medical specializes in therapeutic acute wound care, with its flagship product, the RECELL System, designed to optimize wound healing and accelerate patient recovery [6][8] - The RECELL System is FDA-approved for treating thermal burn wounds and trauma wounds, utilizing a patient's own skin to create Spray-On Skin Cells [6][8]

Core Insights - AVITA Medical, Inc. will report its second quarter 2025 financial results on August 7, 2025, after U.S. market close [1] - A conference call and webcast will be held on the same day to discuss financial results and business highlights [1] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions [3] - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn wounds and full-thickness skin defects, utilizing a patient's own skin to create Spray-On Skin Cells [3] - In the U.S., AVITA Medical has exclusive rights to manufacture and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3] International Market Presence - The RECELL System is approved for various applications in international markets, including burns and full-thickness skin defects [4] - The system is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan [4]

Core Insights - AVITA Medical's RECELL technology demonstrates significant clinical benefits, including reduced hospital stays for burn patients, as highlighted in a recent study presented at the British Burn Association Annual Meeting [1][3] - The RECELL system utilizes a small sample of a patient's skin to create Spray-On Skin™ Cells, which leads to faster healing and less pain compared to traditional skin grafting methods [2][5] - The analysis of over 6,300 patients indicates a reduction in hospital stay by an average of 6.2 days or 35.7% when treated with RECELL compared to split-thickness autografts, resulting in approximately $300 million in cost savings over five years [8] Company Overview - AVITA Medical is a leader in therapeutic acute wound care, focusing on innovative solutions that enhance wound healing and accelerate patient recovery [5] - The RECELL System is FDA-approved for treating thermal burn wounds and full-thickness skin defects, and it is used in over 130 burn centers across the United States [4][5] - The company also holds exclusive rights to manufacture and distribute other wound care products, including PermeaDerm and Cohealyx™ [5] Market Impact - The RECELL technology is gaining traction in international markets, with approvals in Australia, Europe, and Japan for various skin healing applications [6] - The findings from the national registry analysis provide a clearer understanding of how RECELL influences clinical decisions and patient outcomes, reinforcing its economic value in healthcare [3][8]

Core Insights - AVITA Medical, Inc. announced the first clinical publication evaluating Cohealyx™, a collagen-based dermal matrix, which showed significantly faster wound bed vascularization and autograft readiness compared to conventional matrices, achieving readiness in 5 to 10 days instead of the typical two to four weeks [1][2][3] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions to optimize wound healing and accelerate patient recovery [6] - The company’s flagship product, the RECELL System, is FDA-approved for treating thermal burn wounds and full-thickness skin defects, utilizing a patient's own skin to create Spray-On Skin Cells [6][7] Clinical Findings - In a case series at The Ohio State University Wexner Medical Center, two patients with complex hand wounds treated with Cohealyx achieved autograft readiness in 7 to 13 days, demonstrating accelerated integration and vascularization [2][3] - The publication highlights that these outcomes can significantly reduce patient burden and lower associated complication risks [2] Technological Innovation - Cohealyx is bioengineered using proprietary TetraPure Technology, featuring crosslinked, purified collagen types I and III, which supports optimal cellular migration and rapid revascularization [3] - Preclinical studies indicated wound bed readiness as early as day 7, and the recent publication serves as the first clinical validation of these findings [3] Publication Details - The full paper titled "A Bovine Dermal Collagen Matrix (BDCM) Advances Readiness to Autografting: A Case Series" is available online, providing further insights into the clinical efficacy of Cohealyx [4]